[HTML] nih.gov

[HTML][HTML] Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution

M Salati, C Baldessari, B Cerbelli… - … Lung Cancer Research, 2018 - ncbi.nlm.nih.gov
Horn and colleagues (11) reported a 2-year followup update on nivolumab in previously
treated NSCLC by pooling together data from both CheckMate-017 and-057, for squamous …
被引用次数：21 相关文章

Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution.

M Salati, C Baldessari, B Cerbelli… - … Lung Cancer Research, 2018 - europepmc.org
Horn and colleagues (11) reported a 2-year followup update on nivolumab in previously
treated NSCLC by pooling together data from both CheckMate-017 and-057, for squamous …

Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution

M Salati, C Baldessari, B Cerbelli… - … Lung Cancer Research, 2018 - tlcr.amegroups.org
Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution - Salati -
Translational Lung Cancer Research Have a website account?Log In orRegister for …
[PDF] amegroups.cn

[PDF][PDF] Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution

M Salati, C Baldessari, B Cerbelli, A Botticelli - cdn.amegroups.cn
Horn and colleagues (11) reported a 2-year followup update on nivolumab in previously
treated NSCLC by pooling together data from both CheckMate-017 and-057, for squamous …

Nivolumab in pretreated non-small cell lung cancer: Continuing the immunolution

M Salati, C Baldessari, B Cerbelli… - TRANSLATIONAL …, 2018 - iris.uniroma1.it
Nivolumab in pretreated non-small cell lung cancer: Continuing the immunolution IRIS IRIS
Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste Serie IT Italiano Italiano …

[引用][C] Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution

M Salati, C Baldessari, B Cerbelli… - … lung cancer research, 2018 - pubmed.ncbi.nlm.nih.gov
Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution
Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution Transl …
[PDF] researchgate.net

[PDF][PDF] Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution

M Salati, C Baldessari, B Cerbelli, A Botticelli - researchgate.net
Horn and colleagues (11) reported a 2-year followup update on nivolumab in previously
treated NSCLC by pooling together data from both CheckMate-017 and CheckMate-057, for …
[HTML] amegroups.org

[HTML][HTML] Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution

M Salati, C Baldessari, B Cerbelli… - … Lung Cancer Research, 2018 - tlcr.amegroups.org
Lung cancer is still the leading cause of both cancer-related incidence and mortality
worldwide with roughly 1.8 million cases (12.9% of total) and 1.6 million deaths (19.4% of …

Nivolumab in pretreated non-small cell lung cancer: Continuing the immunolution

M Salati, C Baldessari, B Cerbelli… - TRANSLATIONAL …, 2018 - iris.uniroma1.it
Nivolumab in pretreated non-small cell lung cancer: Continuing the immunolution IRIS IRIS
Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste Serie IT Italiano Italiano …